Pathological findings in central nervous system demyelination associated with infliximab.
Alicja Kalinowska-LyszczarzMahboobeh Fereidan-EsfahaniYong GuoClaudia F LucchinettiWilliam Oliver TobinPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2019)
Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.